“…Phosphorylation of B-Myb by cyclin A/Cdk2 in the early S-phase of the cell cycle stimulates the transactivation potential of BMyb by counteracting the repressive function of an inhibitory domain located at the carboxyl-terminus (Robinson et al, 1996;Lane et al, 1997;Sala et al, 1997;Ziebold et al, 1997;Saville and Watson, 1998b;Bartsch et al, 1999). Several B-Myb interacting proteins have been identified and shown to affect the B-Myb transactivation potential, including cyclin D1 (Horstmann et al, 2000;Schubert et al, 2004), poly-(ADP-ribose) polymerase (PARP) (Cervellera and Sala, 2000), p107 (Joaquin et al, 2002), nucleolin (Ying et al, 2000), p300 (Bessa et al, 2001;Johnson et al, 2002;Schubert et al, 2004), TAFII250 (Bartusel and Klempnauer, 2003) and N-CoR/SMRT (Masselink et al, 2001;Li and McDonnell, 2002). The interactions of some of these proteins, such as PARP (Santilli et al, 2001), N-CoR/SMRT (Li and McDonnell, 2002) and p300 (Schubert et al, 2004), appear to be modulated by the phosphorylation state of B-Myb suggesting that they are involved in the phosphorylation-dependent stimulation of B-Myb activity.…”